Evidence map›Paper›PMID 35112095›Full record

ArticleAmerican journal of preventive cardiology2022

HbA1c, Coronary atheroma progression and cardiovascular outcomes.

Iryna Dykun, Ozgur Bayturan, Julie Carlo, Steven E Nissen, Samir R Kapadia, E Murat Tuzcu, Stephen J Nicholls, Rishi Puri

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Iryna DykunC5Research, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
Ozgur BayturanDepartment of Cardiology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey.
Julie CarloC5Research, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
Steven E NissenC5Research, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
Samir R KapadiaC5Research, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
E Murat TuzcuDepartment of Cardiovascular Medicine, Cleveland Clinic Abu Dhabi, UAE.
Stephen J NichollsMonash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia.
Rishi PuriC5Research, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH.
Cleveland Clinic · USManisa Celal Bayar University · TRMonash University · AUWest German Heart and Vascular Center Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsWe tested the hypothesis that on-treatment HbA1c levels independently associate with coronary atheroma progression and major adverse cardiovascular events (MACE: death, myocardial infarction, cerebrovascular accident, coronary revascularization, or hospitalization for unstable angina) rates.

methodsWe performed a

resultsAmong 3,312 patients (mean age 58.6±9years, 28.4%women) average on-treatment HbA1c was 6.2±1.1%. Overall, there was no net significant annualized change in PAV (0.12±0.19%,

conclusionsIndependent of achieved cardiovascular risk factor control, greater HbA1c levels significantly associate with coronary atheroma progression rates and clinical outcomes. These results support the notion of a direct, specific effect of glycemic control upon coronary atheroma and atherosclerotic events, supporting the rationale of therapies designed to directly modulate it.

Indexed as

ACS, acute coronary syndromeAQUARIUS, Aliskiren Quantative Atherosclerosis Regression Intravascular Ultrasound StudyASCVD, atherosclerotic cardiovascular diseaseBMI, body mass indexCoronary atheroma progressionCVD, cardiovascular diseaseDiabetes mellitusGLAGOV, Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular UltrasoundHbA1cHbA1c, hemoglobin A1cHDL-C, high-density lipoprotein cholesterolhsCRP, high-sensitivity-CRPIBIS 2, The Integrated Biomarkers and Imaging Study-2IVUSIVUS, intravascular ultrasonographyLDL-C, lipoprotein cholesterolMACEMACE, major adverse cardiovascular eventsNORMALISE, Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic EvaluationPAV, percent atheroma volumePERISCOPE, Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective EvaluationPVD, peripheral vascular diseaseREVERSAL, Reversal of Atherosclerosis With Aggressive Lipid LoweringSATURN, The Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatinSTRADIVARIUS, Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabont – The Intravascular Ultrasound StudyTG, triglyceridesUKPDS, UK Prospective Diabetes Study

Identifiers

PMID35112095
PMCPMC8790601
OpenAlexW4206378883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.